Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSara ScottANAjay NookaJKJonathan Kaufman

Discussion

Loading...

Member takes

Overview

Observational analysis showed an 88% response rate in relapsed/refractory multiple myeloma with talquetamab bridging therapy, suggesting effective disease management during CAR T-cell manufacturing.

Key Points

  • Talquetamab achieved an overall response rate of 88% during bridging therapy for multiple myeloma, indicating significant efficacy.
  • Patients experienced manageable adverse effects, including dysgeusia and xerostomia, which resolved after therapy cessation.
  • Evaluation included safety measures for adverse effects like hemophagocytic lymphohistiocytosis, ensuring comprehensive patient monitoring.
  • Bridging therapy with talquetamab did not affect the response to subsequent ciltacabtagene autoleucel treatment, maintaining treatment integrity.

Cite This Study

Scott et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7f8https://doi.org/10.1182/blood-2025-2811
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma2025 · 1 citations
  2. 2Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma2025 · 5 citations
  3. 3Bi-specific T-cell engagers as a bridge to ciltacabtagene autoleucel in Relapsed/Refractory multiple myeloma: Real-world outcomes in an underserved urban population2025
  4. 4Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis2025
  5. 5Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma2025 · 10 citations